• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

For the Treatment of Rheumatoid Arthritis, Market Share for TNF-alpha Inhibitors Will Decrease Through 2018

Posted on: Monday, 18 May 2009, 07:00 CDT

Actemra/RoActemra Will Emerge as the Preferred Biological Drug for TNF-Refractory Patients, According to a New Report from Decision Resources

WALTHAM, Mass., May 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, in the treatment of rheumatoid arthritis, the market share for TNF-alpha inhibitors will decrease to 63 percent through 2018 as a result of the increasing use of alternative agents to treat the disease. In 2008, TNF-alpha inhibitors such as Amgen/Wyeth/Takeda's Enbrel and Abbott/Eisai's Humira accounted for 80 percent of rheumatoid arthritis drug sales in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Rheumatoid Arthritis finds that alternative biologics such as Roche/Chugai's Actemra/RoActemra will take market share away from the TNF-alpha inhibitors as interviewed rheumatologists indicate they switch to one of these agents for patients who respond inadequately to two TNF-alpha inhibitors. Actemra/RoActemra will likely emerge as the preferred agent for TNF-refractory patients and is forecasted to achieve sales of nearly $2 billion in 2018.

The report also finds that Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe/Janssen's Simponi has advantages in its drug delivery and efficacy and is expected to take significant market share away from Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe's Remicade. Simponi will also experience greater uptake than UCB/Otsuka's Cimzia, which has launched for the indication following its recent approval for rheumatoid arthritis by the Food and Drug Administration. Additionally, an emerging agent from Pfizer is expected to impact overall sales of biologics in the market.

"We expect Pfizer's CP-690550, which is in Phase III of development, to steal patient share from the TNF-alpha inhibitors, in particular, and constrain the biologics market," said Decision Resources Analyst Joanna Kim, M.Ed. "The potential of this oral Jak-3 inhibitor was demonstrated by its impressive efficacy in a recent Phase II clinical study for rheumatoid arthritis."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact: Decision Resources Decision Resources, Inc. Christopher Comfort Elizabeth Marshall 781-296-2597 781-296-2563 ccomfort@dresources.com emarshall@dresources.com

SOURCE Decision Resources

Source: PR Newswire

More News in this Category